Tags

Type your tag names separated by a space and hit enter

Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis.
Vaccine. 1998 Dec; 16(20):1907-16.V

Abstract

Vaccine efficacies against typical pertussis after household exposure to Bordetella pertussis were estimated to be 75.4% for an acellular five-component vaccine, 42.4% for an acellular two-component vaccine, and 28.5%, for a licensed US whole cell vaccine, compared to placebo. Logistic regression analyses demonstrated statistically significant correlations between clinical protection and the presence of IgG antibodies against pertactin, fimbriae 2/3 and pertussis toxin in pre-exposure sera. Multicomponent pertussis vaccines of proven high efficacy in recent Swedish NIAID-sponsored efficacy trials induced higher antibody levels against pertactin and fimbriae 2/3 than less efficacious vaccines. Anti-pertactin, anti-fimbriae 2/3, and anti-PT may be used as surrogate markers of protection for multicomponent acellular and whole-cell vaccines against pertussis.

Authors+Show Affiliations

Sachs' Children's Hospital, Stockholm, Sweden.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

9796042

Citation

Storsaeter, J, et al. "Levels of Anti-pertussis Antibodies Related to Protection After Household Exposure to Bordetella Pertussis." Vaccine, vol. 16, no. 20, 1998, pp. 1907-16.
Storsaeter J, Hallander HO, Gustafsson L, et al. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine. 1998;16(20):1907-16.
Storsaeter, J., Hallander, H. O., Gustafsson, L., & Olin, P. (1998). Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine, 16(20), 1907-16.
Storsaeter J, et al. Levels of Anti-pertussis Antibodies Related to Protection After Household Exposure to Bordetella Pertussis. Vaccine. 1998;16(20):1907-16. PubMed PMID: 9796042.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. AU - Storsaeter,J, AU - Hallander,H O, AU - Gustafsson,L, AU - Olin,P, PY - 1998/10/31/pubmed PY - 1998/10/31/medline PY - 1998/10/31/entrez SP - 1907 EP - 16 JF - Vaccine JO - Vaccine VL - 16 IS - 20 N2 - Vaccine efficacies against typical pertussis after household exposure to Bordetella pertussis were estimated to be 75.4% for an acellular five-component vaccine, 42.4% for an acellular two-component vaccine, and 28.5%, for a licensed US whole cell vaccine, compared to placebo. Logistic regression analyses demonstrated statistically significant correlations between clinical protection and the presence of IgG antibodies against pertactin, fimbriae 2/3 and pertussis toxin in pre-exposure sera. Multicomponent pertussis vaccines of proven high efficacy in recent Swedish NIAID-sponsored efficacy trials induced higher antibody levels against pertactin and fimbriae 2/3 than less efficacious vaccines. Anti-pertactin, anti-fimbriae 2/3, and anti-PT may be used as surrogate markers of protection for multicomponent acellular and whole-cell vaccines against pertussis. SN - 0264-410X UR - https://www.unboundmedicine.com/medline/citation/9796042/Levels_of_anti_pertussis_antibodies_related_to_protection_after_household_exposure_to_Bordetella_pertussis_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264410X98002278 DB - PRIME DP - Unbound Medicine ER -